Marfella et al. [26] observed significantly lower plasma TNF-α, IL-6 and IL-18 levels, low pro-inflammatory cytokine levels and macrophage infiltration in atherosclerotic lesions of treated SCH patients compared to untreated SCH patients. This evidence concerns the gene IL6 and spindle cell hemangioma.